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Abstract
Background: The genus Trichuris includes parasites of major relevance in veterinary and human medicine. Despite serious
economic losses and enormous impact on public health, treatment options against whipworms are very limited.
Additionally, there is an obvious lack of appropriately characterized experimental infection models. Therefore, a detailed
parasitological characterization of a Trichuris muris isolate was performed in C57BL/10 mice. Subsequently, the in vivo
efficacies of the aminophenylamidines amidantel, deacylated amidantel (dAMD) and tribendimidine as well as the
cyclooctadepsipeptides emodepside and in particular PF1022A were analyzed. This was performed using various
administration routes and treatment schemes targeting histotropic and further developed larval as well as immature and
mature adult stages.
Methodology/Principal Findings: Duration of prepatent period, time-dependent localization of larvae during period of
prepatency as well as the duration of patency of the infection were determined before drugs were tested in the
characterized trichurosis model. Amidantel showed no effect against mature adult T. muris. Tribendimidine showed
significantly higher potency than dAMD after oral treatments (ED50 values of 6.5 vs. 15.1 mg/kg). However, the opposite was
found for intraperitoneal treatments (ED50 values of 15.3 vs. 8.3 mg/kg). When emodepside and PF1022A were compared,
the latter was significantly less effective against mature adults following intraperitoneal (ED50 values of 6.1 vs. 55.7 mg/kg)
or subcutaneous (ED50 values of 15.2 vs. 225.7 mg/kg) administration. Only minimal differences were observed following
oral administration (ED50 values of 2.7 vs. 5.2 mg/kg). Triple and most single oral doses with moderate to high dosages of
PF1022A showed complete efficacy against histotropic second stage larvae (36100 mg/kg or 16250 mg/kg), further
developed larvae (3610 mg/kg or 16100 mg/kg) and immature adults (3610 mg/kg or 16100 mg/kg). Histotropic first
stage larvae were only eliminated after three doses of PF1022A (36100 mg/kg) but not after a single dose.
Conclusions/Significance: These results indicate that the cyclooctadepsipeptides are a drug class with promising
candidates for further evaluation for the treatment of trichurosis of humans and livestock animals in single dose regimens.
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Introduction
About 20 major human helminthoses have a significant impact
on global public health [1]. Since a highly disproportionate share
of the burden occurs in developing areas of sub-Saharan Africa,
Asia and the Americas, helminth infections belong to both, the
‘‘neglected tropical diseases’’ and the ‘‘neglected infections of
poverty’’ [2,3]. In these regions more than a billion people are
infected with one or more worm species [2]. An important part of
human helminth infections worldwide is caused by soil-transmitted
nematodes, including the roundworm Ascaris lumbricoides with 800
million infections, the whipworm Trichuris trichiura with 600 million
infections, and the hookworms Ancylostoma duodenale and Necator
americanus with 600 million infections [4]. An estimated 1.6–6.4
million disability adjusted loss of life years are a direct result of
trichurosis [4]. In 2010 an estimated 5023 million people lived in
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areas stable for transmission of Trichuris trichiura, plus another 284
million lived in areas of unstable transmission of whipworms,
globally [5]. High prevalence often comes along with high
abundance of protein energy malnutrition and anemia as well as
limited access to medical care and educational opportunities [6].
Mild T. trichiura infections are often asymptomatic, but severe and
chronic infections can result in the Trichuris dysentery syndrome
including chronic inflammation of the intestine, rectal prolapse,
anemia, poor growth, and clubbing of the fingers [6].
Despite the strong impact of helminthoses on public health, only
four anthelmintics (albendazole, mebendazole, levamisole, and
pyrantel) with only two different modes of action are listed on the
WHO list of essential medicines to treat soil-transmitted nematode
infections [7] with mebendazole and albendazole being by far the
most commonly used drugs [8]. Whereas both drugs are highly
effective against adult A. lumbricoides in a single dose, only
albendazole is used for the treatment against tissue migrating
larvae – mebendazole is poorly absorbed from the gastrointestinal
tract thus its therapeutic activity is largely confined to adult/
luminal worms [8]. Furthermore, the efficacy of both drugs is
unsatisfactory against hookworms and T. trichiura in single dose
regimen [9]. Higher efficacies against whipworms and hookworms
were observed when albendazole or mebendazole were adminis-
tered using multiple drug administration [10]. However, treat-
ments using multiple doses significantly increase costs and
management efforts in particular in poor communities lacking
efficient public health infrastructure. Moreover, persistent under-
dosing of A. duodenale, N. americanus and T. trichiura within recently
increased large-scaled mass drug administration campaigns against
filariosis and soil-transmitted helminthosis may favor selection of
highly resistant genotypes [9] as already described for T. trichiura
[11].
In addition to its relevance in human medicine, the genus
Trichuris also has an enormous impact on veterinary medicine. For
instance, Trichuris vulpis, the dog whipworm, causes an intestinal
parasitosis of clinical relevance and is also suspected to be zoonotic
[12]. However, several anthelmintics registered for use in dogs
such as diethylcarbamazine, piperazine, ivermectin and pyrantel
lack efficacy against T. vulpis severely limiting the choice of drug
for deworming [12]. In swine, infections with Trichuris suis, the
dose-limiting nematode for all relevant anthelmintic drug classes,
lead to reduced growth rates and therefore result in significant
economic losses [13]. Finally, due to the long period of prepatency
of Trichuris spp. and the lack of efficacy of most drugs against
histotropic larval forms, two blocks with one to three doses each
are usually necessary to completely eliminate the parasites [12].
It is therefore obvious, that the development of new, safe and
highly efficacious drugs to treat soil-transmitted nematode
infections is urgently required. In particular, new drugs for the
treatment of Trichuris spp. using a single dose would significantly
increase treatment options in both, human and veterinary
medicine. Therefore, the evaluation of the efficacy of promising
drug candidates against whipworms is an essential step towards
improvement of anthelmintic treatment opportunities.
To investigate and compare the anthelmintic profiles of new
drug candidates against whipworm infections, the Trichuris muris
mouse model is highly suitable [14]. Trichuris L1 hatch in the small
intestine of their host and migrate rapidly to the caecum and colon
[15], where they invade the epithelium [16] and undergo a
histotropic phase with two molts lasting several days (duration
depends on the particular species and isolate). Then, larvae
migrate to the surface of the epithelium extruding their caudal
ends freely into the lumen of the intestine (further developed larvae
or free larvae) [16]. In general anthelmintics have been reported to
be less effective against histotropic larvae, which might be
attributed to the poor accessibility of drugs to these larvae within
the tissue [12].
In order to eliminate parasites using a single dose or at least a
single treatment block, it is desirable to evaluate drug candidates
not only against mature adult worms but also against histotropic
larvae and further developed immature stages. Since duration of
development and timespan of infection depend on both, the host
strain [17] and whipworm isolate [18], a detailed characterization
of the respective host-parasite relationship is essential. Thus,
localization of larvae in the course of the prepatent period and
onset of patency of the infection have to be analyzed carefully
before in vivo assays against specific stages of T. muris can be
conducted meaningfully with the respective isolate.
The cyclooctadepsipeptides [19] and the aminophenylamidines
[20] are promising anthelmintic classes for further development of
broad-spectrum drugs to treat intestinal nematode infections. The
semi-synthetic cyclooctadepsipeptide emodepside has been shown
to have an almost complete efficacy against immature and mature
stages of T. vulpis in dogs [21] and T. muris in mice [22,23] while
the aminophenylamidines amidantel and tribendimidine showed
only low to moderate efficacy against T. muris in mice [24] and T.
trichiura in humans [25–27].
Both drug classes have completely different target molecules. It
is clear that the aminophenylamidines are agonists of acetylcholine
receptors and have a very similar mode of action as levamisole
[28,29] whereas several targets have been suggested for the
cyclooctadepsipeptides with the voltage-gated, calcium-activated
potassium channel SLO-1 as most important candidate
[19,30,31]. However, the G-protein coupled receptor LAT-1
[32] and ionotropic GABAA receptors [33,34] might also
contribute to susceptibility to cyclooctadepsipeptides.
Therefore, the present study investigated and compared the in
vivo anthelmintic properties of the semi-synthetic cyclooctadepsi-
peptide emodepside, its parental natural fermentation product
Author Summary
Treatment options against whipworm infections of hu-
mans and livestock are very limited and even anthelmintics
recently introduced into the market do not significantly
improve the situation. Here, we evaluated members of two
relatively new drug classes, the aminophenylamidines
(amidantel, deacylated amidantel, tribendimidine) and
the cyclooctadepsipeptides (PF1022A, emodepside) in a
murine trichurosis model. While tribendimidine is licensed
for the treatment of human helminthosis caused by
hookworms, pinworms and roundworms in China, emo-
depside is the nematocidal component of dewormers for
cats and dogs. With the exception of amidantel, all drugs
showed good efficacies against adult whipworms using
three consecutive doses. Due to considerations regarding
drug safety and price, PF1022A was further evaluated
against histotropic first and second stage larvae, further
developed larvae, immature and mature adults using a
single or three consecutive doses. Three doses eliminated
all stages while a single dose was inefficient against
histotropic first stage larvae. In general, higher doses were
required for early stages in comparison to stages protrud-
ing into the gut lumen. Since only a very basic formulation
of drugs was tested, further improvement can be expected
from optimized formulations. Cyclooctadepsipeptides
should therefore be considered as candidates for evalua-
tion to treat Trichuris spp. infections in livestock and
humans.
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PF1022A and the aminophenylamidines amidantel, deacylated
amidantel and tribendimidine against T. muris. Since tribendimi-
dine has previously been reported to have insufficient activity after
oral administration in humans [25–27], drugs were also admin-
istered intraperitoneally and subcutaneously. In addition to the
evaluation of adulticidal efficacy, PF1022A was further tested
against histotropic larvae and further developed immature stages
of whipworms, using single and three consecutive doses.
Materials and Methods
2.1 Ethical statement
All studies presented were conducted at the laboratories of
Bayer HealthCare, Global Drug Discovery, Animal Health in
Monheim, Germany. The experiments were registered and
approved by the State Office for Nature, Environment, Agricul-
ture, and Consumer Protection, North Rhine-Westphalia, Ger-
many (reference number 200/V14), in accordance with 18a,
Section 1 and 2 of the German Protection of Animals Act and the
European Union directive 2010/63/EU.
2.2 Drugs
Amidantel, dAMD, emodepside and PF1022A were available at
Bayer HealthCare AG, Global Drug Discovery Animal Health in
Monheim, Germany. Tribendimidine was obtained from Shan-
dong Xinhua Pharmaceutical Company Limited (Zibo, People’s
Republic of China). All drugs were stored at 4uC until further use.
Individual drug concentrations were prepared separately as
dispersions in Cremophor EL (BASF, Ludwigshafen, Germany)
and deionized-water [1:3] on the days of treatment.
2.3 Animals and parasites
Female SPF inbred mice of the strain C57BL/10 ScSnOlaHsd
(C57BL/10) were purchased from Harlan UK Limited, at four
weeks of age. They were housed in Macrolon cages under
environmentally controlled conditions and kept in groups of five
animals unless otherwise indicated. Water and Sniff rodent food
pellets were available ad libitum. Mice were allowed to acclimate for
exactly seven days before starting any experiments. The T. muris
isolate was kindly provided by Heinz Mehlhorn (Du¨sseldorf,
Germany). A detailed history regarding isolation and passage is
not available.
Mice were orally infected with a gavage using 0.2 ml fresh tap
water with 200 eggs containing fully developed L1 of T. muris.
Murine feces were collected on days 49, 56 and 63 p.i., euthanasia
was performed by carbon dioxide suffocation.
Isolation of the eggs was performed as described in section 2.4.1.
The development of L1 in the eggs was performed in stender
dishes in an incubator at 27uC and 95% humidity for approxi-
mately 8 weeks. Progress of embryonation was controlled weekly.
After development of L1 in.90% of the eggs was completed, eggs
were stored at 4uC until further usage for a maximum of 6 months.
Before infection of mice, the egg suspension was washed with fresh
tap water at room temperature.
2.4 Parasitological characterization of a T. muris life cycle
in C57BL/10 mice
2.4.1 Determination of the periods of prepatency and
patency. To assess the duration of prepatent period, ten mice
were infected. Starting from day 7 p.i., all ten mice were housed on
grids to collect feces for 24 h once a week. During these periods,
the bottom of the cage was covered with 300 ml tap water. Feces
and water were collected in a 1 l beaker and homogenized with a
hand-held blender. Using a wooden spatula, fine components of
the feces were separated from remaining debris by filtration
through a 200 mm sieve and collected in a clean 1 l beaker. The
residues were rinsed with tap water until the filtrate reached a
volume of 600 ml. After sedimentation for 1 h, the supernatants
(approximately 500 ml) were removed. The sediment was
centrifuged at 2,0006g and room temperature for 10 min. The
pellet was resuspended in 200 ml tap water and centrifuged under
the same conditions. After another washing step, the pellet was
resuspended in 200 ml saturated sodium chloride solution. Then,
samples were centrifuged at 2,0006g and room temperature for
5 min, the top 25 ml were filled into a 300-ml beaker and 225 ml
tap water were added. After at least 2 h of sedimentation the
supernatant was decanted and the sediment was washed in tap
water another four times. After decanting the supernatant, the
sediment (approximately 20 ml) was examined for the presence of
eggs. Examination of feces was continued until three consecutive
samples were found to be negative. Three independent experi-
ments with ten mice each were performed.
2.4.2 Variation in egg output in the course of patency of
the infection. To determine the variation in egg output in the
course of patency of the infection, a fecal egg count method was
adapted from Stoll [35]. In brief, 10 mice were infected. Only
animals, positive for eggs in their feces on day 35 p.i., were
included in the study. Starting from day 35 p.i., mice were housed
individually on grids in Macrolon cages to collect individual feces
for 12 h periods once a week. Fecal samples (0.5 g) were weighed
from each mouse, 7.0 ml water were added and incubated for
15 min. Feces were roughly macerated with a wooden spatula
followed by an extensive homogenization using a magnetic stirrer
at low speed until samples were analyzed. For each sample, three
75 ml aliquots were pipetted on microscope slides and eggs were
counted. To obtain the number of eggs per gram feces, the
arithmetic mean of the three counts was multiplied by 200 to
calculate the number of eggs per gram feces (epg). Feces were
analyzed until 15 weeks p.i., since status of patency of the infection
became quite variable afterwards (see 2.4.1 and 3.1.1).
2.4.3 Time course of localization of larvae in the course of
prepatent period. To analyze the time course of the localiza-
tion of larvae during prepatent period the following experiment
was adapted from Panesar [36]. For this experiment 120 mice
were infected. During the first 40 days p.i., three mice were
euthanized daily and their duodena, caeca and colons were
removed and split open. The luminal content was removed and
inspected for any stages of T. muris. Then, the mucosa of the guts
was examined for the presence of worms extruding into the lumen
of the guts. Finally, duodena, caeca and colons were cut into small
squares and separately incubated in 0.85% physiological sodium
chloride solution at 37uC for 24 h. By carefully scraping the
mucosa the histotropic larvae became visible using a dissecting
microscope. Seven mice, in which not a single stage of T. muris was
found, were excluded from the study.
2.4.4 Female/male ratio in the course of infection. On
day 35 p.i., fecal examinations were performed for each of the 60
infected mice individually to confirm patency of the infection.
Only animals found positive for eggs in their feces were included in
the study. Weekly, starting from day 35 until day 152 p.i., three
mice were euthanized and dissected. Female and male whipworms
in caecum and colon were counted. Two independent experiments
with 60 mice in each experiment were performed.
2.4.5 In vitro embryonation of T. muris eggs. The
embryonation of eggs was analyzed and compared under several
different conditions. Freshly isolated and purified eggs were
suspended in (i) 0.5% formaldehyde in physiological sodium
chloride solution, (ii) physiological sodium chloride solution or
Evaluation of Drug Candidates against T. muris
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(iii) tap water and transferred into 40 ml stender dishes (see [37]) to
compare the rate and speed of development. The progress of
embryonation was assessed weekly by microscopic analysis of three
10 ml aliquots. Eggs were counted and categorized as (i)
unembryonated, (ii) partially embryonated, (iii) fully embryonated
or (iv) degraded. The latter category was chosen according to the
following criteria: a) vesicular appearance of unsegmented eggs or
b) deformed larval structures within the eggs.
Furthermore, incubation temperatures of 4uC, 19uC, 27uC and
37uC as well as the influence of the presence of antibiotic (i.e.
10 mg/ml sisomycin plus 1 mg/ml clotrimazole), relative humidity
(75%, 85% and 95%) and light conditions (light versus no light)
were evaluated in tap water using the same method.
Finally, the influence of storage at 4uC after full embryonation
of eggs was compared to storage at 27uC to determine the best
storage condition. After embryonation at 27uC, eggs were stored at
27uC or at 4uC for 70 days. For each incubation temperature, 5
mice were infected. On day 45 p.i., mice were euthanized and
worm counts were determined.
2.5 In vivo efficacy against T. muris in mice
In 24 consecutive experimental blocks, 655 mice were
randomized into 132 groups, each consisting of five animals.
One group of 5 mice was used for each dosage and for each
administration route tested. In each block, 5 infected mice served
as untreated control and received the vehicle only.
2.5.1 In vivo efficacy against mature adult stages of T.
muris. On day 42 p.i., a fecal examination was performed for
each mouse to confirm patency of the infection. Only animals
positive for T. muris eggs in their feces were included in the study.
Based on the individual body weight on day 45 p.i., exact dosages
were calculated. In case of multiple dose regimens, three doses of
the respective drug were administered orally, intraperitoneally or
subcutaneously (nuchal fold) on days 46–48 p.i. Dosages used are
summarized in Table 1. For single doses, 50, 75, 100, 150, 200,
250, 300 or 500 mg/kg PF1022A were administered on day 48 p.i.
On day 49 p.i., mice were euthanized. Subsequently, necropsy was
performed and worms in colons and caeca were counted.
2.5.2 In vivo efficacy against larval and immature adult
stages of T. muris. Based on the parasitological characteriza-
tion (duration of prepatent period and time-dependent localization
of larvae during period of prepatency), the in vivo efficacy of
PF1022A was also investigated against larval and immature adult
stages of T. muris. According to the time course of localization of
developmental stages in the present study and the analysis on the
molting pattern in T. muris [36], the following time points for drug
administration were chosen:
Individual body weight was determined on the day of infection
for L1, on day 11 p.i. for L2 and on day 25 p.i. for further
developed stages. PF1022A dosages of 10, 100, 250, and 500 mg/
kg or 1.0, 10, 50 and 100 mg/kg were administered on day 3 p.i.
or on days 1–3 p.i. to target L1. For the evaluation of efficacy
against the histotropic L2, treatments were carried out with
PF1022A dosages of 10, 100, 250, and 500 mg/kg or 1.0, 10, 50
and 100 mg/kg on day 14 p.i. or on days 12–14 p.i., respectively.
Since the following molts of males and females are less synchronous
[36], treatments were directed against further developed immature
stages in general. Treatments with 1.0, 10, 50 and 100 mg/kg
PF1022A were performed on three consecutive days (26–28 p.i.)
and treatments with 10, 100, 250, and 500 mg/kg PF1022A only on
day 28 p.i. Independently of the targeted stage euthanasia of mice
and worm counts were performed on day 49 p.i.
2.6 Calculation of dose-response curves and statistical
analysis
For parasitological characterization of the T. muris isolate used
in C57BL/10 mice, descriptive statistics were performed using
GraphPad Prism 5.03. Differences in worm counts between
different weeks of infection and in sex ratio were determined by a
One Way ANOVA followed by Dunnet’s post hoc test using the
first week of the patent period as the control against which all
other time points were tested.
Table 1. Single and multiple drug dosages evaluated in vivo against mature adults of T. muris, classified by route of administration.
Dosage (mg/kg) 0.5 1.0 2.5 5.0 7.5 10 15 20 25 50 75 100 150 200 250 300 400 500
PF1022A 36oral X X X X X X X X
16oral X X X X X X X X
36 subcutaneous X X X X X X X X
36 intraperitoneal X X X X X X X X
Emodepside 36oral X X X X X X X X
36 subcutaneous X X X X X X X X




dAMD 36oral X X X X X X
36 subcutaneous X X
36 intraperitoneal X X X X X
Tribendimidine 36oral X X X X X X
36 subcutaneous X X
36 intraperitoneal X X X X X
‘X’ indicated that the respective drug was evaluated in the given dose using the indicated route of administration.
doi:10.1371/journal.pntd.0002698.t001
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For all drugs and routes of administration tested against patent
T. muris infections, the reduction of the worm burden expressed in
percent of the corresponding control groups of 5 mice was plotted
against the log10 of the drug dosages. Efficacies were set to zero if
mean of the worm counts was higher than the mean of the
corresponding control group. Furthermore, the corresponding
SEM values of the affected groups start from 0 (all figures showing
dose- response curves). Four-parameter-logistic curves were fitted
using GraphPad Prism 5.03 [38]. The top was constrained to
values between 0 and 100%. The no-drug controls were set to
1024 mg/kg to allow log10 transformation of dosages. Calculated
ED50 and ED95 values were compared using the extra sum of
squares F test. If multiple tests were performed, p values were
corrected using the Bonferroni-Holmes procedure.
The absolute number of recovered mature adult worms after
treatment against larval and immature adult stages was compared to
the number of worms isolated from the negative controls by using
the non-parametric Kruskal-Wallis test with Dunn’s post hoc test for
identification of significant differences between individual groups.
Results
3.1 Time course of T. muris development in C57BL/10
mice
3.1.1 Periods of prepatency and patency of the
infection. In each of the three independent experiments
determining presence of eggs in feces in weekly intervals, first
eggs were found on day 35 p.i. Therefore, prepatent period lasted
for at least four but not longer than five weeks. None of the mice
that became patent stopped shedding eggs before week 14 p.i.
However, starting from week 15 p.i., samples were much more
heterogeneous. Mice in experiment 1 remained patent at least
until week 16 p.i., whereas animals in experiment 2 stopped
shedding eggs in week 15 p.i. In experiment 3, fecal examination
was negative in week 16 p.i., but was positive in week 17 p.i.,
again. Patency of the infection ended in week 18 p.i.
3.1.2 Detailed analysis on egg shedding. Nine out of ten
mice were found positive for eggs in their feces on day 35 p.i.
Therefore, only a single mouse was excluded from the study.
Furthermore, one individual mouse died on day 67 p.i. and was
only included in the statistics until day 63 p.i. Variation in egg
shedding in the course of patency of the infection is summarized in
Figure 1. Strong variation in individual egg counts was observed,
indicated by the relatively large standard deviations (Figure 1). In
general, the mean eggs per gram feces (epg) increased during the
first three weeks of patency of the infection starting with a mean
epg of 291961182 (range 800–5600) at day 35 p.i. The peak in
egg output was observed in week 8 p.i. (epg = 1220063813, range
4200–19800). Starting from week 9 p.i., a gradual reduction of the
average egg count was observed. In week 14 p.i. the first mouse
was found to be negative for eggs in its feces. In another two mice
patency of the infection ceased in week 15 p.i. For the remaining
five mice the mean (6 SD) of eggs per gram feces was calculated to
be 112061110.5 (range 200–3600) on week 15 p.i., being the final
week of this analysis.
3.1.3 Localization of developmental stages throughout
infection. The analysis of the time course of the migration of T.
muris stages during the period of prepatency revealed distinct
phases of localization. Figure 2 summarizes the trend in absolute
numbers of recovered stages in the course of the prepatent period.
Supplementary Table S1 shows the individual counts divided by
duodenum, caecum, colon and luminal debris.
On days 1–4 p.i. a small number (2.861.9, mean 6 SD) of
embryonated eggs was recovered from the intestinal debris of
duodenum, caecum and colon. After day 5 p.i. no embryonated
eggs were found in the gastrointestinal tract. Free larvae were
identified in the debris of guts also for a very limited period during
the first days after infection. Whereas 9.066.2 free larvae were
recovered between day 1 and day 5 p.i. only one sample on day 8
was found positive for two free larvae. However, starting from day
Figure 1. Analysis on egg shedding in the course of patency of
the infection. The graph shows the arithmetic mean values with
standard deviations of the absolute numbers of eggs per gram feces
between days 35 and 105 p.i. with a group size of nine animals. Due to
the death of one mouse, group size was reduced to eight starting from
day 70 p.i.
doi:10.1371/journal.pntd.0002698.g001
Figure 2. Analysis on the occurrence of specific stages of T.
muris in the course of the period of prepatency. Presented is the
occurrence of first stage larvae in the luminal content of the guts (free
stages), of histotropic first, second and third stage larvae (histotropic
stages) and of third and fourth stage larvae as well as immature and
mature adults attached to the epithelium while extruding their
posterior parts into the lumen of the guts (extruding stages) between
days 1 and 31 p.i. Based on dissection of three mice per time point, the
graph shows three data points for each stage and time point. If the
count was found to be zero for a specific stage in each of the three
independent counts, data points are not shown.
doi:10.1371/journal.pntd.0002698.g002
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27 an increasing number of immature and mature adult worms in
the debris was counted (see Supplementary Table S1).
Histotropic larvae were recovered almost throughout the whole
evaluation period. However, during the period of prepatency two
relative maxima in histotropic larval counts were observed. A high
number of histotropic larvae was detected on days 1 and 2 p.i.
(45.864.5), while only a small number was recovered between
days 3 and 12 p.i. (10.364.1). Starting from day 13 the number
steadily increased until day 19 p.i., where 50.3617.4 larvae were
counted (see Supplementary Table S1). From day 20 p.i. on, the
number of histotropic larvae decreased again and finally, starting
from day 24 p.i., the majority of the guts was found to be negative.
Further developed stages were not found before day 21 p.i. The
number of these stages then increased until day 24 and remained
stable (42.6613.9) until the end of the evaluation period (see
Figure 2). As expected, neither histotropic larvae nor any further
developed stages were found in the duodenum (Supplementary
Table S1). On days 30 and 31, the intestinal debris became
positive for unembryonated eggs, indicating the start of patency of
the infection (Supplementary Table S1).
3.1.4 Worm counts and sex ratio. On day 35 p.i., 107/120
mice harbored a patent infection (infection rate of 89.17%). 13
uninfected mice and 4 mice which had died in the course of the
experiment were exclude from the analysis.
The absolute worm counts per infected host are summarized in
Figure 3A. Mean worm counts were not significantly different
from those on day 35 p.i. up to day 70 p.i. (One Way ANOVA
followed by Dunnet’s post hoc test, p.0.05) although a tendency
to lower and steadily decreasing mean worm counts was observed
already at earlier time-points. Thereafter, mean worm counts
were significantly lower than on day 35 (p,0.01) and a con-
tinuous decrease in recovered worms was observed (Figure 3A).
On day 112 p.i. only five worms per mouse where recovered on
average and finally on days 145 and 152 p.i. only two whipworms
were found in one of the necropsied mice. In addition to the
absolute worm counts, Figure 3B shows the relative sex
distribution of the worms during the same evaluation period.
The male/female ratio was progressively skewed towards male
worms. The ratio was 1:1.27 5 weeks p.i, 1:0.97 9 weeks p.i.,
1:0.56 14 weeks p.i., and 1:0.12 17 weeks p.i. Starting in week 9,
the male/female ratio was significantly higher than on day 35 p.i.
(One Way ANOVA followed by Dunnet’s post hoc test,
p,0.001). From week 18 on, 100% of the recovered worms
were males (see Figure 3B).
3.1.5 Optimized conditions for in vitro embryonation of
T. muris eggs. The influence of different media on the rate and
speed of embryonation were compared. No significant difference
was observed between (i) 0.5% formaldehyde in physiological
sodium chloride solution, (ii) physiological sodium chloride
solution and (iii) tap water (data not shown). Therefore, tap water
was used as medium for the following analyses. The incubation
temperature (4uC, 19uC, 27uC or 37uC) had an enormous impact
on both speed and embryonation rate (Supplementary Table S2).
Speed of embryonation steadily increased with temperature.
However, at 37uC the absolute number of degenerated eggs was
also increased. Additives such as sisomycin plus clotrimazole or
lighting conditions did not influence embryonation and were
therefore neglected. However, relative humidity (75%, 85% and
95%) strongly affected the loss of medium by evaporation and
therefore 95% humidity was chosen for routine purposes.
Finally, the influence on storage temperature on egg infectivity
after full embryonation was tested. Mice infected with eggs stored
at 27uC or at 4uC for at least 70 days were necropsied on day 45
p.i. The infection levels between both groups were not found to
differ significantly, as illustrated by worm counts ranging between
28 and 45 or 12 and 59 (p = 0.69 using the Mann Whitney U test).
3.2 In vivo efficacy of cyclooctadepsipeptides and
aminophenylamidines against T. muris
The average number of worms recovered from caecum and
colon from untreated control mice on day 49 was 33.77615.59.
Worm counts after treatment against developmental stages were
also determined on day 49 p.i. (see 2.5.2), while four mice died
before evaluation and were, therefore, not included in the
statistics. The highest worm count was 80, whereas no worms
were recovered in two cases.
3.2.1 In vivo efficacy of aminophenylamidines against
mature adult stages of T. muris. Three oral doses of
500 mg/kg of the aminophenylamidine amidantel led to no
significant reduction of the worm burden. Since three high
Figure 3. Analysis on the occurrence of T. muris in the course of
patency of the infection. (A) Absolute worm counts in the course of
patency of the infection. The graph shows the arithmetic mean values
and standard deviations of the absolute number of recovered worms
during time with a group size of six animals per time point. Mean worm
counts were compared to day 35 p.i. using One-Way-ANOVA followed
by Dunnet’s post hoc test. **, p,0.01 vs. day 35. (B) Sex ratio of T. muris
in the course of patency of the infection. Graph shows the arithmetic
means with standard deviations of the recovered male worms
expressed as percentage of total recovered worms with a group size
of six animals per time point. ***, p,0.001 vs. day 35.
doi:10.1371/journal.pntd.0002698.g003
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consecutive doses of amidantel did not reduce worm counts in
comparison to the no-drug control, this derivative was not further
evaluated in the present study. In contrast to amidantel, both oral
and intraperitoneal treatments with either tribendimidine or
dAMD resulted in dose-dependent reductions of the T. muris
burden. Dose-response curves for both drugs and both routes of
administration are given in Figure 4. Furthermore, ED50 and
ED95 values with 95% confidence intervals as well as p values from
comparisons between the derivatives and R2 values are summa-
rized in Table 2.
The ED95 of tribendimidine was found to be approximately
eight times lower than the ED95 of dAMD following three oral
consecutive doses, whereas the ED95 of tribendimidine was
approximately four times higher than the ED95 of dAMD after
three intraperitoneal administrations (Table 2). However, three
subcutaneous doses with 100 mg/kg or 500 mg/kg of either
tribendimidine or dAMD had no effect on worm counts in
comparison to the vehicle treated group (data not shown).
3.2.2 In vivo efficacy of cyclooctadepsipeptides against
mature adult stages of T. muris. Three oral, intraperitoneal
or subcutaneous doses of either emodepside or PF1022A on days
46–48 p.i., resulted in dose-dependent reductions of the T. muris
burden. Table 2 summarizes ED50 and ED95 values as well as
comparisons between them by administration route.
By comparing the three routes of administration, oral
treatments diminished the worm burden at significantly lower
doses than intraperitoneal or subcutaneous administrations
(Figure 5A, B, C and Table 2). For emodepside, the ED50 values
for intraperitoneal and subcutaneous treatments were approxi-
mately twofold and fivefold higher than for oral treatment
(Table 2). The differences for PF1022A were even more
pronounced. The ED50 values for intraperitoneal and subcutane-
ous treatments were approximately ten and 43-times higher in
comparison to the ED50 values for the oral treatments.
By comparing the ED50 values of the two cyclooctadepsipep-
tides, the results were very diverse depending on the respective
route of administration. However, the calculated ED50 value for
PF1022A after three intraperitoneal doses was approximately nine
times higher than the ED50 value of emodepside. A comparison of
the two drugs after three subcutaneous doses resulted in an
approximately 15-fold higher ED50 value for PF1022A. Surpris-
ingly, the ED50 value of emodepside using three oral administra-
tions was only twofold lower than that of PF1022A. Since the costs
of PF1022A are much lower than those of emodepside and the
difference between both drugs was only small for oral adminis-
tration, a single oral dose against mature adult stages of T. muris
was only evaluated for PF1022A.
A single oral administration of PF1022A on day 48 p.i. also
resulted in dose-dependent reduction of the whipworm burden. A
dose-response curve was calculated (Figure 5A) and ED50 and
ED95 values with 95% CI as well as R
2 values are presented in
Table 2. The ED50 value for PF1022A using a single oral dose was
approximately 36-fold higher in comparison to the three oral
administrations.
3.2.3 In vivo efficacy of PF1022A against developmental
stages of T. muris. Both single and multiple PF1022A doses on
day 28 and days 26–28 resulted in dose-dependent reductions in
the number of recovered worms (Figure 6A, B and Supplementary
Table S3). While a single administration of 10 mg/kg did not
result in any apparent effects, 100 mg/kg or higher dosages
already eliminated the worm burden completely. Three oral doses
of PF1022A against developmental stages on days 26–28 also
resulted in nearly complete or complete cure rates starting from
10 mg/kg. Therefore, an approximately 10-fold lower dosage of
PF1022A was sufficient to cure the infection with further
developed larval stages and immature adult worms with three
doses in comparison to a single dose.
The efficacy of single and multiple PF1022A doses on day 14
and days 12–14 respectively, targeting the histotropic L2, also
resulted in dose-dependent significant reductions of the worm
burden (Figure 6C, D and Supplementary Table S3). In particular,
three dosages of 100 mg/kg PF1022A or a single administration of
250 mg/kg PF1022A were required for complete elimination of
whipworms.
In contrast to the efficacy against L2, the effects of PF1022A
against L1 were not sufficient in the single dose regimen. While
Figure 4. In vivo dose-response curves of dAMD (blue) and
tribendimidine (red) after oral (A) and intraperitoneal (B)
treatments against mature adults of T. muris. Dose-response
curves show the arithmetic mean values and standard errors of the
mean with a group size of five animals per drug and dose. Efficacy was
calculated as relative number of recovered worms compared to the no-
drug control in percentage. Dosages were log10 transformed and
logistic regressions were calculated with top values constrained
between 0 and 100%. Efficacies were set to zero if mean of the worm
counts was higher than the mean of the corresponding control group.
Furthermore, the corresponding SEM values of the affected groups start
from zero. The no-drug controls were set to 1024 mg/kg to allow log10
transformation of dosages.
doi:10.1371/journal.pntd.0002698.g004
Evaluation of Drug Candidates against T. muris
PLOS Neglected Tropical Diseases | www.plosntds.org 7 February 2014 | Volume 8 | Issue 2 | e2698
three doses of 100 mg/kg PF1022A on days 1–3 p.i. were
sufficient to completely cure the mice, a single dose on day 3 p.i.,
using even 500 mg/kg, was not able to significantly reduce worm
burdens (Figure 6E, F and Supplementary Table S3).
Discussion
The majority of human gastrointestinal nematode infections are
caused by A. lumbricoides, A. duodenale, N. americanus, Strongyloides.
stercoralis and T. trichiura [8]. Whereas available drugs are usually
highly effective against A. lumbricoides in a single dose regimen, at
least multiple dosages of those drugs are required to cure
hookworm, threadworm and particularly whipworm infections.
[9,39].
In addition to the enormous impact on human medicine, the
genus Trichuris, like T. suis, is also considered to be a dose-limiting
nematode for most current anthelmintics in a variety of hosts of
veterinary importance [13]. However, treatment options are often
limited. For example, a large number of drugs (diethylcarbama-
zine, ivermectin, piperazine, pyrantel) registered to treat nematode
infections in dogs are lacking sufficient efficacy against T. vulpis
[12]. Among the new anthelmintics that entered the market in the
recent past, especially the cyclooctadepsipeptides [21–23] and
partially the aminophenylamidines [20,24,27] are active against
Trichuris spp., whereas paraherquamide has only poor efficacy [40]
and monepantel lacks efficacy [41]. For derquantel, only data
describing a high efficacy of the combination with abamectin
against Trichuris ovis have been published [42]. However, if these
effects are attributed to derquantel, abamectin or only the
combination of both needs to be clarified.
Persistent underdosing of Trichuris spp. in both humans (during
the reinforced mass drug administration campaigns against
lymphatic filariasis and soil-transmitted nematodes) and animals
of veterinary importance may favor selection of highly resistant
genotypes [9] as already described for T. trichiura [11]. Therefore,
the urgent need for new drugs for the treatment against Trichuris
spp., preferably in a single dose regimen, is obvious for both
human and veterinary medicine.
Due to the long prepatent period of Trichuris spp. and the lack of
efficacy of most drugs against the histotropic phase of larval forms,
multiple blocks with one to three doses each are usually necessary
to completely eliminate the infections [12]. Larvae of several
gastrointestinal nematode species penetrate into the pits and
glands of the mucosa (e.g. Haemonchus spp., Ostertagia spp.,
Teladorsagia spp.) or even penetrate and feed on individual cells
(e.g. Trichuris spp., Trichinella spp.) to survive the lethargy associated
with molting without losing their place in the gut [43]. These
histotropic larvae are often difficult to eliminate and require higher
or repeated doses when compared with luminal or mucosal stages.
In order to evaluate the effects of drugs against the histotropic
stages of T. muris, a detailed knowledge of the time course of
development within the host is required. Since data in the
literature are often quite old and differ in many observations,
especially regarding the number and the time course of molts (for
review see [15]), the isolate used in the present study was subjected
to an in-depth parasitological analysis. Furthermore, the course of
infection strongly depends on the respective mouse strain [17] and
T. muris isolate [18], making a detailed characterization even more
crucial.
The parasitological data obtained here were in agreement with
findings of Panesar and Croll [16]. They reported, that on day 20
p.i., all larvae were found embedded in the surface epithelium with
their posterior ends extruding into the lumen of the gut. In the
present study, this observation was made from day 21 onwards. In
contrast to Panesar and Croll, we still found a small but significant
number of histotropic stages until day 29 p.i. However, the period
in which histotropic stages were exclusively present was almost the
same. Interestingly, observations by Pike [37] were also in line
with data shown here. They have shown, that the female/male
ratio steadily develops towards more male worms and that male T.
muris survive longer than females, which is in marked contrast to
other parasitic nematode species, where females survive longer
than males [37].
In the present study, no in vivo efficacy of the aminophenyla-
midine amidantel was found against patent T. muris infections in
mice. Three oral doses of 500 mg/kg amidantel did not reduce the
Table 2. Comparison of the in vivo efficacies of the aminophenylamidines amidantel, dAMD and tribendimidine and the
cyclooctadepsipeptides emodepside and PF1022A against patent Trichuris muris infections in mice.
Drug Admin.
ED50 with 95%CI
(in mg/kg) p valuea
ED95 with 95% CI
(in mg/kg) p valueb R2
dAMD 36 oral 15.1 (9.9–22.9) ,0.0001 (vs. 36 tribendimidine oral) 97.3 (28.3–334.2) 0.0007 (vs. 36 tribendimidine oral) 0.8039
36 i.p. 8.3 (7.3–9.5) ,0.0001 (vs. 36 tribendimidine i.p.) 12.8 (10.6–15.4) ,0.0001 (vs. 36 tribendimidine i.p.) 0.9349
Tribendimidine 36 oral 6.5 (6.0–7.2) ,0.0001 (vs. 36 dAMD oral) 12.6 (9.9–15.9) 0.0007 (vs. 36dAMD oral) 0.9447
36 i.p. 15.3 (13.2–17.7) ,0.0001 (vs. 36 dAMD i.p.) 44.8 (30.9–65.0) ,0.0001 (vs. 36 dAMD i.p.) 0.9279
Emodepside 36 oral 2.7 (1.9–3.9) 0.0009 (vs. 36 PF1022A oral) 24.5 (8.7–68.8) 0.3684 (vs. 36 PF1022A oral) 0.8368
36 i.p. 6.1 (4.8–7.7) ,0.0001 (vs. 36 PF1022A i.p.) 40.0 (18.9–84.5) ,0.0001 (vs. 36 PF1022A i.p.) 0.9274
36 s.c. 15.2 (13.0–17.7) ,0.0001 (vs. 36 PF1022A s.c.) 40.7 (24.5–67.4) ,0.0001 (vs. 36 PF1022A s.c.) 0.8481
PF1022A 36 oral 5.2 (4.0–6.8) 0.0009 (vs. 36 emodepside oral) 36.5 (14.9–89.8) 0.3684 (vs. 36 emodepside oral) 0.8681
36 i.p. 55.7 (44.4–70.0) ,0.0001 (vs. 36 emodepside i.p.) 208.5 (99.2–438.2) ,0.0001 (vs. 36 emodepside i.p.) 0.8657
36 s.c. 225.7 (180.2–282.6) ,0.0001 (vs. 36 emodepside s.c.) 515.0 (254.8–1041) ,0.0001 (vs. 36 emodepside s.c.) 0.7432
16 oral 186.6 (111.0–313.5) ,0.0001 (vs. 36 PF1022A oral) 686.7 (168.5–2798) ,0.0001 (vs. 36 PF1022A oral) 0.6086
Presented are the ED50 and ED95 values with 95% confidence intervals (CI) and coefficients of determination (R
2) as well as p values, for determination of significant
differences.
aSignificant difference in ED50 to drug in brackets.
bSignificant difference in ED95 to drug in brackets.
doi:10.1371/journal.pntd.0002698.t002
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worm burden in comparison to the no-drug control. The efficacy
of amidantel against T. muris was investigated previously and was
also found to be only moderate [24]. Therefore, amidantel was not
further evaluated in the presented study. In contrast, three
consecutive oral doses with either tribendimidine or dAMD
resulted in ED50 values of 6.5 mg/kg and 15.1 mg/kg, respec-
tively. Complete elimination of the worm burden was achieved by
three oral doses using either 25 mg/kg tribendimidine or 100 mg/
kg dAMD. Oral doses of 16400 mg [44] or 36400 mg [26]
tribendimidine have been shown to result in cure rates of 76.8%
and 33.3%, respectively, against T. trichiura in humans. Intraper-
itoneal injections of the drugs, which to our knowledge were
evaluated for the first time, resulted in reversed potency with ED50
values of 15.3 mg/kg for tribendimidine and 8.3 mg/kg for
dAMD and complete elimination at dosages above 50 mg/kg in
both cases. This is somewhat surprising since tribendimidine is
known to rapidly disintegrate in aqueous environments releasing
two molecules of dAMD [45]. Differences in release of the highly
hydrophobic drugs from the used formulation (dispersion
containing Cremophor EL/deionized water) are the most likely
explanation for the observed phenomenon. The larger tribendi-
midine molecule can be suspected to diffuse more slowly into the
aqueous environment. It can be assumed that release of drugs
from the dispersion occurs more rapidly in the digestive track
under mechanical mixing in the presence of bile salts than in the
peritoneum and that passive diffusion is of minor importance in
the gut. The absence of efficacy of tribendimidine and dAMD
using subcutaneous administrations might also be due to the very
basic formulation of the drugs. However, neither intraperitoneal
nor subcutaneous administrations, using such a basic formulation,
were able to significantly improve the efficacy of tribendimidine or
dAMD against T. muris in mice.
In contrast to the aminophenylamidines, the cyclooctadepsipep-
tide, emodepside, has previously been shown to be completely
effective against T. vulpis [21] and also T. muris [22,23]. A single
dosage of 7.16 mg/kg emodepside in the Profender spot on
formulation for cats was sufficient to clear patent T. muris
infections of mice within 48 h [22] and even treatments of mice
against immature stages using 6.0 mg/kg emodespide of the same
formulation on day 3, day 20 or day 35 p.i., resulted in
significantly reduced worm counts (.95% efficacy) [23]. Next to
the oral tablet formulation of Profender for dogs with 1 mg/kg
emodepside [21], also a single dose of 0.45 mg/kg emodepside of
the oral Procox suspension was sufficient to completely eliminate
immature and mature T. vulpis from dogs [46]. However, almost
all investigations on the efficacy and safety of emodepside were
conducted on nematodes of veterinary importance and only few in
vitro data on important nematodes of humans are available [47],
and PF1022A has not been evaluated against Trichuris spp. at all.
However, while no clinical signs of intolerability were found, a
high degree of efficacy against a large number of helminths in a
variety of hosts including Heligmosomoides bakeri in mice [48],
Strongyloides ratti and Nippostrongylus brasiliensis in rats, Ancylostoma
caninum in dogs, cyathostomes in horses, Trichostrongylus colubriformis
and Haemonchus contortus in sheep and Dictyocaulus viviparus in cattle
using fairly low dosages of 1–10 mg/kg PF1022A were reported
[49].
There were also differences in efficacy comparing emodepside
and PF1022A in the present study, but the magnitude of these
Figure 5. In vivo dose-response curves of emodepside (red) and
PF1022A (blue) after oral (A), intraperitoneal (B) or subcuta-
neous (C) treatments against mature adults of T. muris. Dose-
response curves show the arithmetic mean values with standard errors
of the mean with a group size of five animals per drug and dose.
Efficacy was calculated as relative number of recovered worms
compared to the no-drug control in percentage. Dosages were log10
transformed and logistic regressions were calculated with top values
constrained between 0 and 100%. Triangles indicate a single dose of
PF1022A (light blue), circles three doses of PF1022A (dark blue) and
squares three doses of emodepside (red). Efficacies were set to zero if
mean of the worm counts was higher than the mean of the
corresponding control group. Furthermore, the corresponding SEM
values of the affected groups start from zero. The no-drug controls were
set to 1024 mg/kg to allow log10 transformation of dosages.
doi:10.1371/journal.pntd.0002698.g005
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differences was dependent on the route of administration.
However, emodepside always performed significantly better than
PF1022A using the ED50 value as criterion. The difference
between both drugs was particularly small for the oral adminis-
tration, which also performed better than the intraperitoneal and
the subcutaneous route. The ED50 and ED95 values for PF1022A
were only 1.9 and 1.5 fold higher than those for emodepside,
respectively.
For its suitability in mass-drug-treatment programs, drugs need
a high safety and production costs should be as low as possible.
Figure 6. In vivo efficacy of PF1022A against L3, L4 and immature adults (A, B), histotropic L2 (C, D) and histotropic L1 (E, F) of T.
muris using both, single (A, C, E) and triple (B, D, F) dose regimens. Box plots show the median numbers and quartiles of recovered adult T.
muris after treatment against immature stages with wiskers representing minimal and maximal values. Group sizes were 5 mice per drug and dose. +,
arithmetic mean; *, p,0.01 vs. control; **, p,0.001 vs. control.
doi:10.1371/journal.pntd.0002698.g006
Evaluation of Drug Candidates against T. muris
PLOS Neglected Tropical Diseases | www.plosntds.org 10 February 2014 | Volume 8 | Issue 2 | e2698
Due to the fact that the class of aminophenylamidines is still
considered to be potentially hazardous [50] and PF1022A does
have much cheaper production costs than emodepside (due to
omission of semi-synthetic derivatization) [47], single dose
experiments and treatments targeting developmental stages were
only performed with PF1022A. In addition, no data regarding the
effects of PF1022A on any stages of Trichuris spp. have been
published previously. To examine whether PF1022A has the
potential to replace the more expensive emodepside in therapy of
Trichuris spp., it is important to determine the suitability of
PF1022A as a broad-spectrum anthelmintic.
At least in the triple dose regimen, PF1022A was able to
completely eliminate all developmental stages of T. muris.
However, the required dosages inversely correlated with the time
span after infection, i.e. the earlier stages had to be treated with
higher dosages. Single drug administration needed 2.5 to 10-fold
higher dosages to achieve complete resolution of the infections,
and against L1 larvae no significant effect on worm burdens could
be obtained using only a single dose. The most likely reason for
this observation is the localization of the larvae. Larvae develop
deep in the epithelium of the basal parts of the crypts of
Lieberku¨hn until day 5 p.i., while they were found closer to the
surface of the epithelium between days 5 and 10 p.i. On day 15
p.i., a large proportion of histotropic larvae was already found in
the epithelial surface, where a higher drug concentration might be
present [16].
One might think that the relatively high dosages of PF1022A
required to completely eliminate developmental T. muris stages,
especially in single dose regimens, could prevent its further
development as trichuricidal drug. However, potential improve-
ment of efficacy through optimized galenic formulations should be
taken into account. The potential of cyclooctadepsipeptides for
efficient treatment against Trichuris spp. has been shown using
single oral administration of Profender tablets (Bayer Animal
Health GmbH, Leverkusen, Germany). A dose rate of 1 mg/kg
emodepside resulted in almost complete elimination of immature
and mature stages of T. vulpis in dogs (.99%) [20], suggesting that
optimized formulations can dramatically improve drug perfor-
mance in this drug class. The formulation in Profender tablets is
optimized to eliminate all relevant parasitic nematodes of dogs and
optimization can be considered to improve drug efficacy.
Emodepside is also the only nematocidal ingredient of Profender
spot-on for cats and Procox suspension for puppies. Although
using a different route of administration (dermal) Mehlhorn et al.
[22] have shown that a single dosage of 7.16 mg/kg emodepside in
the Profender spot on formulation for cats was sufficient to clear T.
muris infections of mice within 48 h. In sharp contrast to that, three
consecutive oral doses of 75 mg/kg emodepside using the
Cremophor EL/water dispersion were required to achieve a
complete elimination of patent T. muris infections in the present
study. The more than 10-fold increase in efficacy between three
doses using Cremophor/water and a single dose using the
optimized Profender formulation emphasizes that every drug
formulation has to be optimized for each drug and host species
and that dramatic decreases in required drug dosages are possible
when using an optimized formulation. In addition, optimization of
formulations also decreases the risk of intoxications and the costs
of treatment, in particular, if drugs can be targeted specifically
towards the location of the parasite, e.g., the gut, avoiding high
drug concentrations in tissues, e.g., the brain, which may be
important for side effects.
In conclusion, in vivo treatments with relatively high doses of
PF1022A resulted in complete elimination of Trichuris muris,
including mature adult and immature adult worms as well as
histotropic and further developed larval stages in a single-dose
regimen. Since only non-optimized formulations were evaluated in
this study, considerably lower dosages might be achievable, using
formulations optimized for particular host species. Despite the fact
that detailed safety and pharmacokinetic studies are still
completely missing for humans, distinct effects of PF1022A against
the usually dose-limiting genus Trichuris in the mouse model
suggest that cyclooctadepsipeptides are useful candidates for
development as agents against human soil-transmitted hel-
minthoses and nematode infections of livestock animals.
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